Subscribe
istock-619963760_sudok1
sudok1 / iStockphoto.com
17 October 2018Americas

FDA lifts hold on first human CRISPR trial

The US Food and Drug Administration (FDA) has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
US university treats cancer patients with CRISPR
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
US university treats cancer patients with CRISPR
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

More on this story

Americas
Google fund invests in CRISPR start-up
14 May 2019   Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Americas
US university treats cancer patients with CRISPR
17 April 2019   The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Biotechnology
AstraZeneca to launch CRISPR-based cancer research centre
11 December 2018   Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud
US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug